Skip to main content
. 2016 Jul 15;5(9):e1211220. doi: 10.1080/2162402X.2016.1211220

Figure 6.

Figure 6.

Antitumor activity of ULBP2-aCD19-aCD19 in an immunodeficient (NSG) mouse model. 5 × 106 MEC1 cells were subcutaneously (s.c.) transplanted into 21 NSG mice. Two days later, 4 × 105 PBMC from a healthy donor together with 15 µg of ULBP2-aCD19-aCD19 were injected (i.v.) into seven mice while another seven mice were left untreated (control group). Remaining seven mice were either treated with 4 × 105 PBMC alone (four mice) or in combination with 15 µg of a non-specific immunoligand ULBP2-aPSMA (three mice). (A) Tumor growth for each mouse was measured at regular interval using the formula for tumor volume (L × W × H/2). Results show the measurements until day 28 (when all the mice were alive) and are depicted as mean (SEM) of seven mice in “no treatment” (•), “PBMC ± U-PSMA” (▪) and “ULBP2 + U-19-19” (▴) group, respectively. For simplicity, statistical significance between “No treatment” and “PBMC + U-19-19” groups are shown. (*p < 0.05; **p < 0.01). (B) Mice were sacrificed when the tumor volume reached 1,000 mm3. The study was continued for 51 d since the tumor challenge with no signs of tumor development in “U-19-19” treatment group and mice in this group were censored at the end of the study. Survival curve of “PBMC + U-19-19” group was significantly different from “PBMC ± U-PSMA” (p = 0.0003) and “No treatment” group (p = 0.0002) while there was no significant difference between “PBMC ± U-PSMA” and “No treatment” groups (p = 0.568). (Two tailed p value < 0.0167 was considered as significant; 0.0167 was Bonferroni-corrected threshold). (C) Tumor size in individual mouse at day 32 showing late onset of tumor growth in mice treated with PBMC + U-PSMA (non-specific immunoligand; ▴) compared to PBMC (▪) treated mice (*p < 0.05; **p < 0.01). (D) Days required for tumor volume to reach 1,000 mm3 in individual mouse in all control groups. Despite late onset of tumor growth in three mice within “PBMC + U-PSMA” (▴) group, tumor in these mice progressed much quicker and required similar time-point as “no treatment” (•) and “PBMC” (▪) groups to reach 1,000 mm3.